

Broad Dengue Neutralization in Mosquitoes Expressing an Engineered Antibody

Anna Buchman^{1&}, Stephanie Gamez^{1&}, Ming Li¹, Igor Antoshechkin³, Shin-Hang Lee^{4,5,6}, Shin-Wei Wang^{5,6}, Chun-Hong Chen^{5,6}, Melissa J. Klein⁷, Jean-Bernard Duchemin^{7#}, James E. Crowe, Jr.^{8,9}, Prasad N. Paradkar^{7*}, and Omar S. Akbari^{1,2*}

Affiliations

¹ Section of Cell and Developmental Biology, University of California, San Diego, La Jolla, California, USA

² Tata Institute for Genetics and Society-UCSD, La Jolla, California, USA

³ Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, California, USA

⁴ Institute of Biotechnology, National Tsing Hua University, Hsinchu, Taiwan

⁵ National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan, Taiwan

⁶ National Mosquito-Borne Diseases Control Research Center, National Health Research Institutes, Zhunan, Taiwan

⁷ CSIRO Health and Biosecurity, Australian Animal Health Laboratory, 5 Portarlington Road, Geelong, VIC, 3220, Australia

⁸ Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA

⁹ Departments of Pediatrics, Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA

#Current Address: Institut Pasteur de la Guyane, Cayenne, French Guiana

*Correspondence to: oakbari@ucsd.edu & Prasad.Paradkar@csiro.au

& equal contributions

Abstract

With dengue virus (DENV) becoming endemic in tropical and subtropical regions worldwide, there is a pressing global demand for effective strategies to control the mosquitoes that spread this disease. Recent advances in genetic engineering technologies have made it possible to create mosquitoes with reduced vector competence, limiting their ability to acquire and transmit pathogens. Here we describe the development of *Aedes aegypti* mosquitoes synthetically engineered to impede vector competence to DENV. These mosquitoes express a gene encoding an engineered single-chain variable fragment derived from a broadly neutralizing DENV human monoclonal antibody and have significantly reduced viral infection, dissemination, and transmission rates for all four major antigenically distinct DENV serotypes. Importantly, this is the first engineered approach that targets all DENV serotypes, which is crucial for effective disease suppression. These results provide a compelling route for developing effective genetic-based DENV control strategies, which could be extended to curtail other arboviruses.

Significance Statement

Here we describe the development of *Ae. aegypti* mosquitoes synthetically engineered to impede vector competence to multiple serotypes of DENV. Given the global significance of DENV, these mosquitoes may be used to curtail Dengue transmission by this potent vector.

Introduction

Dengue fever is a devastating viral disease caused by several antigenically distinct dengue viral (DENV) serotypes that are all dangerous to humans but cannot be readily controlled using broad-spectrum techniques^{1,2}. Transmitted by infected mosquitoes, DENV infection typically manifests as severe fever, headaches, and myalgia³ and can advance to the life-threatening dengue hemorrhagic fever and dengue shock syndrome⁴. Global incidences of DENV and its associated economic burden have increased dramatically in recent years^{5,6}, with over 50% of the world's population now at risk of infection⁷ and 390 million documented infections per year⁶ for an estimated \$40 billion in economic losses annually^{8,9}. Moreover, there are currently no specific treatments nor preventive prophylactic measures¹⁰ because the single commercially available vaccine¹¹ is only partially effective¹², and due to increased risk of severe dengue illness and hospitalization among certain groups, its use is prevented in many contexts¹³⁻¹⁵. Therefore, control of the disease-spreading mosquitoes is currently the best option for preventing DENV transmission¹³.

*Aedes aegypti*¹⁶, the main vector of DENV and other epidemiologically significant viruses such as chikungunya (CHIKV), yellow fever (YFV), and Zika (ZIKV), is a domestic endophilic mosquito¹⁷ that has expanded its habitable range in recent decades¹⁸ and will likely continue to spread¹⁹. Current control measures including the removal of standing water and the use of chemical insecticides have had limited success in reducing *Aedes* populations²⁰ and, thereby, incidences of DENV²¹, and can instead cause insecticide resistance and behavioral changes such as a shift in biting times^{22,23}. Therefore, novel vector control strategies²⁴, like the use of genetically modified mosquitoes to either suppress mosquito populations or render mosquitoes unable to transmit pathogens²⁵, are increasingly needed. For example, the development and deployment of a genetic

Sterile Insect Technique (SIT)-like system termed Release of Insect Dominant Lethal (RIDL) has had some success in reducing *Aedes* mosquito populations in the wild^{26,27}. Moreover, releases of mosquitoes artificially infected with the intracellular endosymbiont *Wolbachia*, which can make infected males incapable of successfully mating with uninfected females in an SIT-like manner and can inhibit mosquito infection with pathogens such as DENV and ZIKV^{28,29}, have also been carried out to either suppress mosquito populations or make them less likely to transmit pathogens, and may hold promise for reducing incidence of disease^{30,31}. However, these technologies require releases of large numbers of insects - and must be carried out on an ongoing basis for RIDL and *Wolbachia*-based SIT - for continued vector control, which is laborious and expensive.

Therefore, there has been increasing interest in the development of engineered gene-drive technologies, which are able to rapidly transmit themselves and any linked “cargo” genes, such as anti-pathogen effectors, through wild disease-transmitting populations^{25,32,33} such that only a few releases of modest amounts of engineered insects could drive desirable cargo genes through wild populations, making them efficient and cost effective for vector control. To achieve disease reduction, such gene-drive systems need to be linked to useful “cargo”, such as effective anti-pathogen genes, and several approaches for engineering *Ae. aegypti* resistance to DENV have been attempted. For example, one study used RNA interference by employing inverted RNA repeats to target DENV-2 in a conditional and tissue-specific manner^{34,35}, while another described miRNA cassettes targeting DENV-3 that reduced viral transmission rates³⁶. In addition to using synthetic small RNAs, others have taken advantage of the mosquito’s innate antiviral JAK/STAT pathway to increase resistance to DENV-2 and DENV-4³⁷. However, all previous approaches have been limited by their ability to target only one or two—not all four—major DENV serotypes. Because hyperendemicity of DENV in tropical areas is frequent⁵ and secondary DENV infection has been

linked to severe dengue disease (SDD), refractory mosquitoes should be capable of blocking all serotypes or risk being ineffective in controlling dengue epidemics. Therefore, better anti-DENV effectors are needed.

Broadly neutralizing antibodies may be especially promising as anti-DENV effector gene candidates because of their ability to neutralize antigenically diverse viruses³⁸. However, while engineered monoclonal antibodies that confer resistance to *Plasmodium*, a protozoan parasite that causes malaria, have been expressed in *Anopheles* mosquitoes³⁹⁻⁴¹, none targeting a virus have been described in any mosquito species. Previously, a DENV-targeting 1C19 monoclonal antibody (MAb) was identified from a large panel of naturally occurring MAbs from human subjects following vaccination or natural infection⁴². *In vitro* studies demonstrated that this antibody neutralized viruses from all major DENV serotypes and was capable of significantly reducing viremia in a mouse model after DENV-1 and DENV-2 infection⁴². Here, we engineer *Ae. aegypti* to express a 1C19-based, broadly neutralizing, single-chain variable fragment (scFv) that is capable of neutralizing all four DENV serotypes⁴². Crucially, we demonstrate that mosquitoes expressing this anti-DENV scFv cannot be infected with or transmit any of the four DENV serotypes and have few significant fitness costs conferred by the presence of the antibody. These results provide a promising route for developing effective DENV control strategies using genetically engineered mosquitoes.

Results

Generation of DENV-resistant mosquitoes

To determine whether expressing an anti-DENV antibody in mosquitoes could confer resistance to DENV, we first needed to engineer a broadly neutralizing antibody that was compatible with mosquitoes and could be expressed *in vivo* in its desired form. We chose 1C19 as our model due to its ability to cross-neutralize multiple DENV serotypes in humans⁴². As it is a human monoclonal antibody, however, it cannot be unobtrusively expressed in mosquitoes, so a new form that is both compatible with mosquitoes and maintains its neutralization capabilities had to be designed. We then choose to engineer an scFv comprising the linked variable heavy (VH) and light (VL) chains because this format removes the human-specific constant region that could impart difficulties in a mosquito and it can be expressed in one “chunk” in an organism without the need for additional *in vivo* processing. To do this, sequences for the 1C19 VH and VL chains were obtained from hybridoma cells expressing the human monoclonal antibody⁴². We then engineered a scFv comprising the VH and VL domains of 1C19 linked using a 15-amino-acid repeating glycine-serine [G(4)S]3 linker⁴³ that was codon-optimized for *Ae. aegypti*. We also engineered a version of this 1C19 scFv that was fused with a 3' 30-amino-acid human influenza hemagglutinin (HA) epitope tag, commonly used as a general expression tag, reasoning that it might be useful in downstream expression analyses. To conditionally drive expression of the 1C19 scFvs in the midgut of female mosquitoes following a blood meal, which would ensure 1C19 expression any time the mosquito was in contact with DENV, we used the *Ae. aegypti* carboxypeptidase (CP) promoter⁴⁴ that induces expression in the midgut following blood ingestion (Figure 1A). The engineered anti-DENV transgenes (termed plasmid OA984 for the untagged version and plasmid OA984-HA for the HA-tagged version) also contained an eye-specific 3xP3

promoter⁴⁵, driving expression of tdTomato as a fluorescent transgenesis marker. Following the typical transgenesis procedure in mosquitoes, consisting of embryonic microinjection and G₀ outcrossing, multiple independent transgenic lines (n = 6) were readily identified in the G₁ generation via the robust expression of tdTomato fluorescence; three of the lines with the strongest marker expression (termed Transgenic Anti-DENV [TADV]-A, containing OA984; and TADV-B and C, containing OA984-HA) were selected for further experiments. We carried out inverse PCR (iPCR) on genomic DNA extracted from the transgenic mosquitoes to verify the transgene insertion site and performed backcrosses to WT for multiple generations to ensure that the transgenic lines represented single chromosomal insertions, and were able to confirm that, in all three independent lines, the anti-DENV transgenes were stably integrated into single chromosomes.

Expression of 1C19 scFv antibody

Robust expression and processing of 1C19 scFv transcripts is required for proper neutralization of DENV, and it is important to know if such expression perturbs global gene-expression patterns, which might interfere with the fitness of the mosquito. To confirm this, we sequenced total RNA populations from dissected midgut tissues isolated from both blood-fed and non-blood-fed female Higgs wildtype (WT) or TADV-A, B, or C mosquitoes using an Illumina platform. We detected robust expression of the 1C19 scFv mRNA in both non-blood-fed and 24-hour post-blood-fed transgenic mosquitoes of all three lines, with clearly increased expression levels at 24-hours post-blood meal, while no expression was observed in the midguts of female WT mosquitoes, suggesting that expression of the 1C19 scFv antibody is transgene-dependent and blood-meal-inducible (~2.35-14.45 fold) as was intended. Importantly, there appeared to be no

major shifts in global gene expression patterns between WT and TADV mosquitoes, suggesting that the 1C19 scFv expression did not globally affect gene-expression patterns (Figure S1, Supplementary Table S4).

To confirm the proper expression of the 1C19 scFv, we performed western blots on dissected midgut tissue from non-blood-fed and blood-fed WT and TADV-A as well as blood-fed TADV-B and TADV-C female mosquitoes using either a custom anti-1C19 scFv antibody, or an anti-HA antibody. Blot analyses revealed that the 1C19 scFv peptide was efficiently expressed following a blood meal exclusively in transgenic mosquitoes (Figure S2). Altogether, these results suggest that the anti-DENV transgene is stably integrated into the mosquito genome and that the DENV-targeting 1C19 antibody is expressed in an appropriate context (i.e., in the midgut following a blood meal) for DENV suppression.

Engineered mosquitoes are resistant to infection with all four DENV serotypes

To determine the functional significance of anti-DENV 1C19 scFv expression on vector competence, the DENV-2 infection rates of the three transgenic TADV lines were first compared to that of WT. To do this, adult females (WT or TADV-A, B, or C) were exposed to serotype DENV-2 (isolate ET300, Genbank EF440433) via membrane blood feeding. At 4 days post infection (dpi), midguts from blood-fed mosquitoes were dissected, and DENV RNA copies were measured using RT-qPCR. All three lines showed a significant reduction in midgut infection rate (45 to 71%) and viral RNA levels (2 to 3 log lower) compared with WT control mosquitoes (infection rate 92%) (Figure S3; Table S1). Since no significant difference in DENV-2 midgut infection levels was detected between the three transgenic lines, TADV-A, which exhibited the

strongest antiviral phenotype (Figure S3; Table S1), was selected for further comprehensive characterization.

For a more detailed study of the TADV-A DENV vector competence, the effect of transgene zygosity on the infection rate was determined by exposing additional adult females (WT or TADV-A) to serotype DENV-2 and analyzing the dissected midguts at 4 dpi. Results from three biological replicates revealed that none of the TADV-A mosquitoes homozygous for the transgene ($n = 35$) were positive for DENV-2 infection in the midguts (Figure 1B). DENV-2 infection was detected in 85.4% (35/41) of the TADV-A mosquitoes that were heterozygous for the transgene; however, these mosquitoes had significantly ($p < 0.001$) lower ($\sim 3 \log_{10}$) viral RNA levels (8.20×10^1 genome equivalent [GE]) than the WT (4.25×10^4 GE) (Figure 1B, Table 1).

To assay for viral dissemination to the rest of the mosquito body, total RNA was collected from whole TADV-A mosquito carcasses (without midguts) and dissected midguts from both homozygous and heterozygous mosquitoes at 14 dpi. The results from three biological replicates indicated that none of the homozygous TADV-A mosquitoes ($n = 30$) were positive for viral replication (dissemination) in either the midgut or the midgut-free carcass (Figure 1B, Table 1). DENV-2 prevalence was detected in 86.6% (26/30) of heterozygous TADV-A mosquitoes in both the carcass and midgut; however, they also had significantly ($p < 0.001$) lower levels of viral RNA ($\sim 3 \log_{10}$) compared to the WT (Figure 1B, Table 1). Finally, as transmission occurs through the saliva, viral transmission rates were determined by collecting the saliva from individual mosquitoes at 14 dpi and measuring the DENV-2 titers using an assay for the median tissue culture infective dose (TCID₅₀). No DENV-2 was detected in the saliva of homozygous TADV-A mosquitoes ($n = 30$) (Figure 1B), though it was detected in 83.3% (25/30) of heterozygous TADV-A mosquitoes; however, here again the DENV-2 titers were significantly ($p < 0.001$) lower

(3.56×10^2 TCID₅₀/ml/mosquito) than the WT mosquitoes (2.70×10^5 TCID₅₀/ml/mosquito) (Figure 1B, Table 1).

To determine whether the anti-DENV 1C19 scFv is broadly inhibitory for other DENV serotypes, the vector competence of TADV-A mosquitoes was assessed using DENV-1 (isolate ET243, GenBank EF440432), DENV-3 (isolate ET209, Genbank EF440434), and DENV-4 (isolate ET288, Genbank EF440435). Tests for infection, dissemination, and transmission were carried out as above, and the results, presented together in Figure 1B and Table 1, were comparable to those obtained with the DENV-2 serotype. In short, the TADV-A mosquitoes homozygous for the transgene proved to be refractory to infection with all three additional serotypes also showing no infection in their midguts at 4 dpi (DENV-1 n = 28; DENV-3 n = 30; DENV-4 n = 27). Even at 14 dpi, there was no sign of viral replication in the midgut or carcass for all tested specimens, and none of the saliva samples (DENV-1 n = 28; DENV-3 n = 30; DENV-4 n = 28) were positive for the virus. As with DENV-2, the mosquitoes heterozygous for the transgene still tested positive for the virus in most specimens, though the overall DENV titers were significantly lower than compared to the WT in all cases (Figure 1B; Table 1).

Engineered anti-DENV mosquitoes outperform *Wolbachia*

To compare the inhibitory effect of the anti-DENV 1C19 scFv to DENV inhibition through *Wolbachia*⁴⁷⁻⁴⁹ infection, we challenged WT mosquitoes infected with *Wolbachia* (*wMel*) with DENV-2. Vector competence results revealed that midguts from mosquitoes infected with *Wolbachia* had significantly ($p < 0.001$) reduced DENV-2 RNA levels (4.75×10^1 GE) at 4 dpi compared with the WT (4.25×10^4 GE) (Figure 2A, Table 1). Similarly, viral dissemination at 14 dpi was also reduced ($p < 0.001$) in *wMel* mosquitoes ($\sim 3 \log_{10}$), and DENV titers in mosquito

saliva at 14 dpi were significantly ($p < 0.01$) lower ($\sim 3 \log_{10}$) in *w*Mel mosquitoes (4.90×10^1 TCID₅₀/ml/mosquito) than in the WT (2.70×10^5 TCID₅₀/ml/mosquito) (Figure 1B, Table 1). Importantly, a direct comparison revealed that the TADV-A mosquitoes are significantly ($p < 0.001$) more effective as homozygotes, and similarly effective as heterozygotes, at blocking DENV infection as *Wolbachia*-infected mosquitoes.

Transgene impact on fitness

To determine whether the anti-DENV 1C19 scFv had any significant fitness effects on transgenic mosquitoes, we assessed several fitness parameters including larval to pupal development time, male and female fecundity and fertility, male mating success, and longevity (Table 2). No significant differences were observed between WT and TADV-A mosquitoes when examining male mating success and fecundity and fertility in both males and females ($p > 0.05$). However, we noticed a significant difference in larval to pupal development times ($p < 0.0001$), with WT mosquitoes developing, on average, 0.8 days faster than TADV-A mosquitoes. When assessing mosquito survivorship, there was no significant difference between WT and TADV-A males ($p > 0.05$; Figure S4), though, WT female mosquitoes lived, on average, 4.5 days longer than TADV-A females ($p < 0.05$; Figure S4). The longevity of infected mosquitoes was also assessed. Transgenic, WT, or *w*Mel mosquitoes were infected with four DENV serotypes and their survivorship was assessed 14 dpi (Table 2). No significant ($p > 0.01$) differences between WT and TADV-A longevity upon infection with serotypes DENV-2, -3, and -4 were observed. However, there was a significant difference in survival upon infection with serotype DENV-1, with a higher proportion of WT mosquitoes surviving at 14 dpi ($p < 0.01$; Table 2, Figure S4). In addition, a

significant difference in survival between *w*Mel mosquitoes and WT and TADV-A mosquitoes infected with serotype DENV-2 was observed ($p < 0.0001$; Figure S4).

Discussion

Our results demonstrate that conditional expression of the anti-DENV 1C19 scFv renders mosquitoes refractory to all four major DENV serotypes and therefore appears to be a potent viral inhibition strategy. While mosquitoes homozygous for the anti-DENV 1C19 scFv showed complete refractoriness to DENV infection, heterozygous mosquitoes were still partially refractory to DENV infection, dissemination, and transmission, with significant, several orders-of-magnitude reductions in viral titers in the saliva. Based on previous findings, it is likely that this significant reduction in viral titers would be sufficient to render heterozygous mosquitoes unable to transmit DENV to a susceptible host⁵⁰. Though this remains to be demonstrated, our results show that heterozygous 1C19 scFv antibody-expressing transgenic mosquitoes are just as efficient at viral suppression as—and homozygous mosquitoes are significantly more efficient than—*Wolbachia*-infected mosquitoes, which are currently being released for DENV control because they are known to be refractory to DENV⁴⁷.

The difference in refractory levels in the homozygous versus heterozygous mosquitoes also suggests that the refractory phenotype is particularly sensitive to scFv antibody expression levels, a phenomenon previously observed with anti-malarial scFv transgenes³⁹ and anti-ZIKV synthetic small RNA transgenes⁵¹. If this means that complete refractoriness is susceptible to positional effects, e.g., not refractory when the scFv antibody transgene is expressed from a different, possibly more weakly expressing genomic insertion position, the identification of more robust midgut-specific promoters may help to ensure sufficiently high expression levels from a single

copy of the transgene regardless of insertion site, as can the use of multiple anti-DENV scFv antibodies in a single transgene^{39,41}.

The strategy we describe here provides an efficient “cargo” gene that can be coupled with a gene-drive system to reduce or eliminate the risk of DENV transmission by mosquitoes. Given the success of previous efforts to develop Cas9-mediated homing-based gene drives in *Anopheles stephensi*⁵², the malaria vector, it should be possible to develop such drives in *Ae. aegypti*. Additionally, since homing-based drive systems quickly convert heterozygotes to homozygotes²⁵, linking the anti-DENV 1C19 scFv antibody described here to such a drive system could, in theory, rapidly convert wild mosquito populations into transgenic homozygotes that would be completely resistant to DENV transmission. Of paramount importance to the viability of such an approach is the evolutionary stability of the refractory transgene, specifically in terms of the likelihood of viral-resistant evolution. Indeed, several studies have shown that, in some contexts, DENV can rapidly evolve resistance in response to neutralizing antibodies^{53,54}, although this can be managed through the selection of antibodies with mechanisms/epitopes that minimize the chance of evolved resistance and the use of a combination of distinct anti-DENV antibodies, many of which have been described (e.g.,^{42,53–56}). The deployment of such a pan-serotype-targeting strategy could serve as an effective component of a comprehensive program to reduce the incidence and impact of DENV.

Due to similarities within viral families, this research could have far-reaching consequences for rendering mosquitoes resistant to other arboviruses like ZIKV and CHIKV by using similar genetic engineering strategies to develop scFv-based transgenes. Multiple potent antibodies that effectively neutralize these various mosquito-borne viruses have also been identified in the last decade^{57–61}. Although not all of these will confer robust viral resistance when

expressed *in vivo* in mosquitoes, the availability of diverse, well-characterized antibodies of this sort, largely as a result of antibody therapeutic development efforts⁵⁸, should allow for the identification of those that function within the desired context. Given the increasing incidence of disease caused by these viruses and the resulting global health implications, such scFv-based transgenes (coupled with gene-drive systems) can provide an effective, sustainable, and comprehensive strategy for reducing the impact of arboviral mosquito-borne diseases.

Author Contributions

A.B., P.N.P., C.H.C., and O.S.A. conceived and designed the experiments. A.B., S.G., M.L., S-H.L., and S-W.W. performed all molecular and genetic experiments. I.A. performed sequencing and bioinformatic analysis. J.E.C. provided sequence data for the 1C19 monoclonal antibody. M.J.K., J.B.D., and P.N.P. performed and analyzed all data for DENV mosquito challenge assays. All authors contributed to the writing and approved the final manuscript.

Acknowledgements

This work was supported in part by a Defense Advanced Research Project Agency (DARPA) Safe Genes Program Grant (HR0011-17-2- 0047) awarded to O.S.A. and a NIH Exploratory/Developmental Research Grant Award (1R21AI123937) awarded to O.S.A and CSIRO internal funding to P.N.P. We thank Prof. Scott O'Neill (Institute of Vector Borne Diseases, Monash University, Australia) and the World Mosquito Program for providing *Wolbachia*-infected mosquito eggs.

Data Availability Statement

All sequencing data associated with this study are available from the NCBI sequence read archive (SRA) accession ID: PRJNA510258. The complete annotated plasmid sequence and DNA is publicly available at Addgene (plasmid #120362 [OA984-HA] and #120363 [OA984]). Transgenic mosquitoes will be made available by the corresponding authors upon request.

Competing interests

J.E.C. has served as a consultant for Takeda Vaccines, Sanofi Pasteur, Pfizer, and Novavax, is on the Scientific Advisory Boards of CompuVax, GigaGen, Meissa Vaccines, and is the Founder of IDBiologics, Inc. All other authors declare no competing financial interests.

Materials and Methods

Anti-DENV scFv design

Sequences for the 1C19 variable heavy and light chains were obtained from hybridoma cells expressing the human monoclonal antibody⁴² that had been cloned biologically by flow cytometry. RNA was extracted using the RNeasy kit (Qiagen #74104), and RT-PCR amplification of antibody gene cDNAs was performed using primer sets designed to detect all human antibody variable gene sequences⁴². The sequence of the antibody cDNAs was determined by automated Sanger sequence analysis. The sequence analysis of the antibody variable gene sequences in the cDNAs was performed using the international ImMunoGeneTics information system (IMGT).

The variable regions of 1C19 were joined by a 15-amino-acid repeating glycine-serine [G(4)S]₃ linker⁴³ to encode a scFv form of the antibody⁶². These chain regions were codon optimized for *Ae. aegypti* expression and then gene synthesized into a vector (GenScript, Piscataway, NJ). For OA984-HA, a 3' 30-amino-acid human influenza hemagglutinin (HA) epitope tag with a G(4)S linker⁶³ was added to the carboxy terminus of the single chain antibody for protein expression verification.

Plasmid assembly

To generate vector OA984 (the anti-DENV scFv-antibody transgene), several components were cloned into the *PiggyBac* plasmid pBac[3xP3-DsRed] (a kind gift from R. Harrell) using Gibson assembly/enzymatic assembly (EA) cloning⁶⁴. First, a *Drosophila* codon-optimized tdTomato marker was amplified with primers 984.1A and 984.1B (Supplementary Table S2 for all primers) from a gene synthesized vector (GenScript, Piscataway, NJ) and cloned into a XhoI/FseI-digested pBac[3xP3-DsRed] backbone using EA cloning. The resulting plasmid was digested with AscI, and the following components were cloned in via EA cloning: the predicted *Ae. aegypti* carboxypeptidase promoter⁴⁴ amplified from *Ae. aegypti* genomic DNA using primers 984.2A and 984.2B, a GFP sequence amplified from vector pMos[3xP3-eGFP]⁶⁵ with primers 984.3A and 984.3B, and a 677-bp p10 3' untranslated region (UTR) amplified with primers 984.4A and 984.4B from vector pJFRC81-10XUAS-IVS-Syn21-GFP-p10 (Addgene plasmid #36432). The anti-DENV scFv was then subcloned into the final vector from a gene-synthesized plasmid (GenScript, Piscataway, NJ) using PmeI and PacI sites and traditional ligation cloning. Annotated plasmid sequences and plasmid DNA are available via Addgene (plasmid #120363).

To generate vector OA984-HA (anti-DENV scFv with HA-epitope tag), the G(4)S linker and HAx3 tag were amplified with primers 984B.C1 and 984B.C2 from the *ninaE*[SBP-His] vector containing these components⁶⁶ and cloned into the PacI digested OA984 backbone using EA cloning. Annotated plasmid sequences and plasmid DNA are available via Addgene (plasmid #120362). All primer sequences used to generate these plasmids are listed in Table S2.

Generation of transgenic mosquitoes

Germline transformations were carried out largely as described⁶⁷. Briefly, 0–1 hr old Higgs wildtype (WT) *Ae. aegypti* pre-blastoderm embryos were injected with a mixture of vector OA984 or OA984-HA (200 ng/ μ L) and a source of *PiggyBac* transposase (200 ng/ μ L)⁶⁵; the injected embryos were hatched in deoxygenated H₂O. A total of 127 surviving WT adult G₀ males and 115 surviving WT adult G₀ females were recovered after the injection. Microinjected WT G₀ adults were assigned to 48 pools and outcrossed to WT of the opposite sex in medium-sized cages. Larvae were fed ground fish food (TetraMin Tropical Flakes, Tetra Werke, Melle, Germany) and adults were fed with 0.3 M aqueous sucrose. Adult females were blood fed three to five days after eclosion using anesthetized mice. All animals were handled in accordance with the Guide for the Care and Use of Laboratory Animals as recommended by the National Institutes of Health, and the methods were supervised by the local Institutional Animal Care and Use Committee (IACUC). A total of 38,177 WT G₁s were screened. G₁ larvae with strong positive fluorescent signals (3xp3-tdTomato) were selected under the fluorescent stereomicroscope (Leica M165FC) and were separated into six individual groups characterized by fluorescence patterning and intensity. One single transgenic male from each group was then allowed to separately mate with 10 WT females to isolate each independent line. Three independent lines, TADV-A (vector OA984), TADV-B

(vector OA984-HA), and TADV-C (vector OA984-HA) with the strongest fluorescence expression patterns were selected for further characterization. To determine whether these lines represented single chromosomal insertions, we backcrossed single individuals from each of the lines for four generations to WT stock and measured the Mendelian transmission ratios in each generation; in all cases, we observed a 50% transmission ratio, indicating single-chromosome insertion. For one of the three lines (TADV-A), transgenic mosquitoes were inbred for at least 20 generations to generate a homozygous stock. Mosquito husbandry was performed under standard conditions as previously described ⁶⁸.

Characterization of insertion sites

To characterize the insertion site of vector OA984 or OA984-HA in transgenic mosquitoes, we adapted a previously described inverse polymerase chain reaction (iPCR) protocol ⁶⁹ as follows. First, genomic DNA (gDNA) was extracted from 10 transgenic fourth instar larvae using the DNeasy Blood & Tissue Kit (Qiagen #69504) per the manufacturer's protocol. Two separate restriction digests were performed on the gDNA (at 100 ng/ μ L) to characterize the 5' and 3' ends of the *PiggyBac* insertion using *Sau3AI* (5' reaction) or *HinP1I* (3' reaction) restriction enzymes. A ligation step using NEB T4 DNA Ligase (NEB #M0202S) was performed on the restriction digest products to circularize digested gDNA fragments, and two subsequent rounds of PCR were carried out per ligation using the corresponding *PiggyBac* primers listed in Supplementary Table S3. The final PCR products were cleaned up using the MinElute PCR Purification Kit (Qiagen #28004) in accordance with the manufacturer's protocol and were sequenced via Sanger sequencing (Source BioScience, Nottingham, UK). To confirm the transgene insertion locus and orientation via PCR, primers were designed based on iPCR-mapped genomic regions and used in

tandem with *PiggyBac* primers based on their location as listed in Supplementary Table S3. Sequencing data then was blasted to the *AeagL5.0* reference genome⁷⁰. The sequencing data was aligned with SeqManPro (DNASTAR, Madison, WI) to determine the orientation of the transgene insertion site. Analysis of the sequencing data indicated that the insertion site for TADV-A is on chromosome 2 (approximate position 310,340,476), the insertion site for TADV-B is on chromosome 2 (approximate position 301,489,980), and the insertion site for TADV-C is on chromosome 1 (approximate position 30,451,048) when aligned to the *AeagL5* assembly (GenBank assembly accession: GCA_002204515.1)⁴⁶.

Total RNA extraction, isolation, and sequencing

Total RNA was extracted from the midguts of non-blood-fed and 24-hours post-blood-fed TADV-A, TADV-B, TADV-C or WT adult females using the Ambion mirVana mRNA Isolation Kit (ThermoFisher Scientific #AM1560). Following extraction, the RNA was treated with Ambion Turbo DNase (ThermoFisher Scientific #AM2238). The RNA quality was assessed using an RNA 6000 Pico Kit for Bioanalyzer (Agilent Technologies #5067-1513) and a NanoDrop 1000 UV-vis spectrophotometer (NanoDrop Technologies/Thermo Scientific, Wilmington, DE). mRNA was isolated using an NEBNext Poly(A) mRNA Magnetic Isolation Module (NEB #E7490), and libraries were constructed using an NEBNext Ultra II RNA Library Prep Kit for Illumina (NEB #E7770). The libraries were quantified using a Qubit dsDNA HS Kit (ThermoFisher Scientific #Q32854) and a High Sensitivity DNA Kit for Bioanalyzer (Agilent Technologies #5067-4626) and sequenced on an Illumina HiSeq2500 in single-read mode with a read length of 50 nt and sequencing depth of 30 million reads per library following the manufacturer's instructions. Reads were mapped to the *Ae. aegypti* genome (*AeagL5.0*) supplemented with the 1C19 cDNA sequence

using STAR aligner ⁷¹, and the expression levels were determined with featureCounts ⁷² (Supplementary Table S4). Correlation coefficients of the transcripts-per-million (TPM) values between WT and transgenic animals were calculated in R[14] and plotted with ggplot2 (Figure S1). All sequencing data can be accessed at NCBI SRA (study accession ID PRJNA510258).

Western blot assays

The general western blot protocol was adapted from CSH Protocols: SDS-PAGE of Proteins ⁷⁴. Briefly, 5–7 days post eclosion, midguts from 25 non-blood-fed and 16-hour post-blood-meal heterozygous TADV-A transgenic and WT mosquitoes were dissected and collected in 1x PBS. Protein samples from dissected tissues were extracted with ice-cold radioimmunoprecipitation assay buffer (RIPA buffer; 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.25% Na-deoxycholate, 1% NP-40, 1 mM EDTA). The protein concentration was measured using Protein Assay Dye (Bio-Rad, Cat. No#5000006) and multi-detection microplate readers (Molecular Devices, SpectraMax M2). Next, 40 µg of total protein were run on a 12% SDS-PAGE and transferred onto a 0.45 µm Immobilon®-P Transfer Membrane (Merck Millipore, Cat. NO#IPVH00010). The membrane was hybridized with a custom antibody at a 1 µg/mL dilution (GenScript, Item number: U3233DA170_2) to directly recognize the 1c19 scFv peptide (26.3KDa) as well as a monoclonal antibody specific to the HA tag for lines TADV-B and C (Cell Signaling, #3724S) at a 1:1,000 dilution; these were subsequently detected by using rabbit IgG antibody (HRP) (GeneTex, Cat. No#GTX 213110-01) at a 1:10,000 dilution. Images were generated by applying the chemiluminescent HRP substrate (Millipore, Cat. No#WBKLS0500) to the blots.

DENV infection of mosquitoes and virus determination

All experiments were performed under biosafety level 3 (BSL-3) conditions in the insectary at the Australian Animal Health Laboratory. The following DENV strains were used for all viral challenge experiments: DENV-1 (isolate ET243, GenBank EF440432), DENV-2 (isolate ET300, GenBank EF440433), DENV-3 (isolate ET209, GenBank EF440434), DENV-4 (isolate ET288, GenBank EF440435). The virus was passaged in Vero cell monolayer cultures before use for mosquito infections. WT or transgenic (confirmed by red fluorescence in the eye) mosquitoes were exposed to DENV as described previously⁷⁵. Briefly, female mosquitoes were challenged with an infected blood meal (TCID₅₀ /mL) through membrane feeding using chicken blood and skin. For infection frequency and virus titer, mosquito midguts were collected at 4 dpi. For dissemination and transmission frequency, mosquito saliva, midguts, and carcasses were collected at 14 dpi. Mosquito saliva was used to determine viral titers using a TCID₅₀ assay on Vero cell monolayer cultures. Midguts and carcasses were used to determine the presence of viral RNA using RT-qPCR against NS5. Mosquito viral challenge, processing, saliva testing, and molecular analyses of infection and dissemination were carried out as previously described⁷⁵. DENV infection frequency was defined by the number of midguts (day 4) found positive for viral nucleic acid. Similarly, the dissemination frequency was calculated by the number of carcasses (day 14) found positive by qPCR. Transmission frequency was defined by the number of TCID₅₀-positive saliva samples over the number tested. These different frequencies and average TCID₅₀ values were compared by the Student's two-tailed t-test.

Confirmation of transgene zygosity

Both homozygous and heterozygous (generated by crossing out homozygous individuals to WT) mosquitoes were used for assays. To confirm the zygosity of tested transgenic mosquitoes,

mosquito heads were homogenized using a bead-beater device for DNA extraction in 30 μ L of extraction buffer (1x Tris-EDTA, 0.1 M EDTA, 1 M NaCl, and 2.5 μ M proteinase K) and incubated at 56°C for 5 minutes and then at 98°C for 5 minutes. The first round of PCR was performed to test for the presence of the anti-DENV transgene using primers 991.3F1 and 1018.S19 (Supplementary Table S3). Another round of PCR then was performed using primers 1018.S19 and 1018.S21 (Supplementary Table S3) to amplify the WT insertion locus (i.e., locus lacking transgene insertion) and thus determine zygosity. For TADV-B, primer set 991.3R2 and 1018.S73 was used to amplify the anti-DENV transgene and primer set 1018.S73 and 1018.S74 were used to amplify the WT insertion site. For TADV-C, primer sets 991.3F2 and 1018.S80 and set 1018.S80 and 1018.S82 were used to amplify the anti-DENV transgene and WT insertion site, respectively. WT mosquitoes served as controls to ensure that the WT locus was successfully amplified in the genetic background. A PCR kit (ThermoFisher Scientific #F553S) with a 57°C annealing temperature was used for all PCRs following standard protocols.

Generation of wMel *Wolbachia* Line and Infection Assay

Eggs of *Ae. aegypti* infected with the *Wolbachia* strain wMel were obtained from the World Mosquito Program (Prof. Scott O'Neill, Monash University). WT mosquitoes infected with wMel were generated by crossing wMel⁺ females with males from the WT line, and the resulting offspring were used for DENV infection experiments. At the end of the experiment, the *Wolbachia* infection status of these mosquitoes was tested using PCR with primers specific for wMel detection⁷⁶ (Supplementary Table S3). The PCRs indicated the presence of wMel in >90% of mosquitoes, and only results from these positive mosquitoes were used for further analysis.

Fitness evaluation on transgenic anti-DENV mosquitoes

To determine if the anti-DENV transgene conferred a fitness cost, several fitness parameters were evaluated in TADV-A transgenic heterozygous and sibling WT mosquitoes. The evaluations of all experimental and control replicates were performed simultaneously. Insectary conditions were maintained at 28°C and 70 to 80% in relative humidity with a 12 hr light/dark cycle. To assess the larval to pupal development time, the eggs were vacuum hatched, and the larvae were distributed into pans (50 larvae per pan) containing 2.5 L of ddH₂O and 0.6 mL of fish food slurry. To determine the larval to pupal development time of transgenic and WT control mosquitoes, the larvae were allowed to pupate, and pupae were collected and counted every day until no pupae were left. To assess female fertility and fecundity, 90 WT and transgenic females were mated to 20 WT males in a cage. After four days, the females were blood fed and individually transferred into plastic vials filled with water and lined with egg paper. After three days, egg papers were collected, and the eggs were counted and vacuum hatched in nine-ounce plastic cups. Starting on the fourth day, the larvae were counted every day until no larvae were present. Female fecundity refers to the number of eggs laid per female, and fertility reflects the number of eggs hatching to produce larvae. To measure male mating success, fecundity, and fertility, one TADV-A transgenic or WT male was mated to five WT females in a single mesh-covered cup filled with water and lined with egg paper. Three days post blood meal, the cups were checked for the presence of eggs, which were collected, counted, and hatched. Hatched larvae were then counted every day until no larvae were present. Male mating success was calculated as the percentage of single male outcrosses that produced larvae. Fecundity was measured as the number of eggs laid per cup; fertility was determined by the number of hatching larvae in each cup. Finally, to assess mosquito longevity, equal numbers of male and female TADV-A transgenic or WT mosquitoes were placed

in medium-sized cages (in triplicate). Mosquitoes that died were counted and removed daily until all mosquitoes had died. Statistical analyses were performed using GraphPad Prism software (GraphPad Software, La Jolla, California, USA). The means were compared using unpaired t tests with Welch's correction, with the exception of male mating success that did not use Welch's correction. The analyses of mosquito survivorship used the Mantel-Cox test. *P* values > 0.05 were considered not significant.




Figure 1. Effect of anti-dengue virus (DENV) single-chain variable fragment (scFv) on DENV titers of TADV-A, *Wolbachia*-infected (*wMel*), and wildtype (WT) mosquitoes. **(A)** Schematic of experiment. TADV-A mosquitoes were generated via transgenesis with the anti-DENV construct, and TADV-A, *wMel*, and WT mosquitoes were then challenged with a blood meal infected with one of four DENV serotypes (DENV-1, isolate ET243; DENV-2, isolate ET300; DENV-3, isolate ET209; or DENV-4, isolate ET288). After the infected blood meal enters the mosquito midgut, there are two potential outcomes: in the first (applies for all tested strains), the virus replicates and disseminates past the midgut to become transmissible; in the second (applies to TADV-A mosquitoes), the anti-DENV transgene expresses scFv antibodies in the midgut that bind to the virus and neutralize it. **(B)** Plots depicting viral titers. To determine if the anti-DENV transgene confers resistance to all four DENV serotypes, we determined viral titers in extracted midguts, carcasses, and saliva from WT, TADV-A (homozygous [Hm] and heterozygous [Ht]), and *wMel* infected mosquitoes. Viral genome equivalents (GE) from mosquito midguts (at 4 days post infection [dpi]) and carcass (at 14 dpi) were determined using RT-qPCR and calculated using

previously published methods. Viral titers in the saliva were determined using the median tissue culture infective dose (TCID₅₀) on Vero cells. For each experiment, data from three replicates is pooled. Red horizontal bars represent the mean GE/viral titer. ** $p < 0.001$.

Table 1. Anti-DENV scFv effect on DENV infection, dissemination, and transmission rates. DENV titers in WT, heterozygous and homozygous TADV-A (TADV-A_{Ht} and TADV-A_{Hm}, respectively), and *wMel* mosquitoes following a blood meal infected with one of four DENV serotypes are shown. DENV GE from mosquito midguts (at 4 or 14 dpi) and carcasses (14 dpi) of WT, TADV-A, and *wMel* (for DENV-2 only) mosquitoes were determined using RT-qPCR and calculated using previously published methods. Viral titers in saliva collected from WT, TADV-A, and *wMel* mosquitoes at 14 dpi were determined using TCID₅₀ on Vero cells.

DENV GE or viral titer on indicated dpi from specified tissue (proportion of mosquitoes with detected virus ; percentage of mosquitoes with detected virus)					
DENV Serotype	Strain	4 dpi	14 dpi		
		Midgut-GE	Midgut-GE	Carcass-GE	Saliva-viral titer
DENV-1	WT	5.70 x 10 ³ (29/35; 83%)	3.80 x 10 ⁵ (35/40; 88%)	4.80 x 10 ⁵ (35/40; 88%)	3.04 x 10 ⁵ (35/40; 88%)
	TADV-A _{Ht}	5.00 x 10 ¹ (20/28; 71%)	3.70 x 10 ² (25/30; 83%)	2.40 x 10 ² (25/30; 83%)	2.50 x 10 ² (25/30; 83%)
	TADV-A _{Hm}	0.00 x 10 ¹ (0/28; 0%)	0.00 x 10 ¹ (0/28; 0%)	0.00 x 10 ¹ (0/28; 0%)	0.00 x 10 ¹ (0/28; 0%)
DENV-2	WT	4.25 x 10 ⁴ (34/40; 85%)	4.40 x 10 ⁵ (40/46; 87%)	5.35 x 10 ⁵ (40/46; 87%)	2.70 x 10 ⁵ (38/46; 83%)
	TADV-A _{Ht}	8.20 x 10 ¹ (35/41; 85.4%)	3.90 x 10 ² (26/30; 86.6%)	6.70 x 10 ² (26/30; 87%)	3.56 x 10 ² (25/30; 83.3%)
	<i>wMel</i>	4.75 x 10 ¹ (43/48; 90%)	5.10 x 10 ¹ (38/48; 79%)	6.45 x 10 ¹ (38/48; 79%)	4.90 x 10 ¹ (35/48; 73%)
	TADV-A _{Hm}	0.00 x 10 ¹ (0/35; 0%)	0.00 x 10 ¹ (0/30; 0%)	0.00 x 10 ¹ (0/30; 0%)	0.00 x 10 ¹ (0/30; 0%)

DENV-3	WT	1.80 x 10 ⁴ (23/30; 77%)	2.90 x 10 ⁵ (29/35; 83%)	3.50 x 10 ⁵ (29/35; 83%)	2.90 x 10 ⁵ (29/35; 83%)
	TADV-A _{Ht}	3.60 x 10 ¹ (22/30; 73%)	1.58 x 10 ² (20/30; 66%)	1.60 x 10 ² (20/30; 67%)	1.33 x 10 ² (20/30; 67%)
	TADV-A _{Hm}	0.00 x 10 ¹ (0/30; 0%)			
DENV-4	WT	3.25 x 10 ³ (25/30; 83%)	3.80 x 10 ⁴ (25/32; 78%)	1.50 x 10 ⁵ (25/32; 78%)	1.60 x 10 ⁵ (25/32; 78%)
	TADV-A _{Ht}	3.40 x 10 ¹ (22/30; 73%)	2.38 x 10 ² (19/28; 68%)	2.95 x 10 ² (19/28; 68%)	1.08 x 10 ² (19/28; 68%)
	TADV-A _{Hm}	0.00 x 10 ¹ (0/27; 0%)	0.00 x 10 ¹ (0/28; 0%)	0.00 x 10 ¹ (0/28; 0%)	0.00 x 10 ¹ (0/28; 0%)

Table 2. Effect of anti-DENV scFv on fitness. Comparisons of several fitness parameters (left-most column) between WT (second column from left) and TADV-A mosquitoes (third column from left) suggest that there are few significant differences (right-most column) between the two groups, indicating that the anti-DENV scFv does not have a major impact on mosquito fitness. The survivorship of infected and non-infected mosquitoes is also shown. The median survival in days was determined for non-infected mosquitoes, and the percent of surviving mosquitoes separately infected by four DENV serotypes was assessed at 14 dpi.

Fitness Parameter	Strain		P-value
	WT (N)	TADV-A (N)	
Female fecundity ^{0†§}	103.6 ± 3.8 (60; 6,213)	110.2 ± 4.4 (57; 5,756)	0.2578
Egg hatchability ^{0l§}	67.5 ± 3.2 (60; 4,208)	61.0 ± 4.1 (57; 4,046)	0.2149
Male mating success ^{0o¶}	93.00 ± 0.04 (43)	95.00 ± 0.04 (37)	0.7756
Male fecundity ^{0l§}	226.3 ± 15.7 (43; 9,730)	202.7 ± 17.2 (37; 7,318)	0.3141
Egg hatchability ^{0III§}	75.9 ± 4.5 (43; 7,558)	73.1 ± 3.9 (37; 5,624)	0.6260
Larval to pupal development in days ^{0§}	6.70 ± 0.77 (1,322)	7.50 ± 0.09 (774)	<0.0001
Female median survival in days ^{††}	53 (122)	48.5 (128)	0.0129
Male median survival in days ^{††}	14 (175)	14 (184)	0.1781
% Survival at 14 dpi with DENV-1 ^{‡‡}	80.8 (26)	43.5 (23)	0.0086

% Survival at 14 dpi with DENV-2 ^{‡††}	72.7 (33)	69.2 (34)	0.6891
% Survival at 14 dpi with DENV-3 ^{‡††}	64.9 (37)	52.2 (46)	0.2679
% Survival at 14 dpi with DENV-4 ^{‡††}	41.3 (138)	48.8 (41)	0.7256

[°]Mean \pm SEM reported.

[†]Average number of eggs laid per female (Number of females scored; total number of eggs counted).

[‡]Percentage of laid eggs that produced larvae (Number of females scored; total number of larvae counted).

[°]Percentage of single male outcrosses that gave rise to viable progeny.

[‡]Average number of eggs laid per single male outcross (Number of male outcrosses scored; total number of eggs counted).

^{‡‡}Percentage of laid eggs that produced larvae per single male outcross (Number of male outcrosses scored; total number of larvae counted).


[§]Unpaired t test with Welch's correction was used.

[¶]Unpaired t test was used to evaluate the statistical significance between the proportions of fertile males.


^{††}Mantel-Cox test was used.

[‡]Percentage of infected mosquitoes surviving at 14 dpi.


Supplementary Figures and Tables




Supplementary Figure 1. Expression correlation analyses of gene expression levels (indicated by TPM [transcripts per million] values) in dissected midgut tissues from WT or transgenic (TADV-A, -B, or -C) mosquitoes without a blood meal (**A**) and 24 hours after a blood meal (**B**). The y-axis corresponds to TPM values in WT samples, and the x-axis corresponds to TPM values in respective transgenic samples. Blue-colored points represent endogenous genes, and red-colored points represent the 1C19 scFv. Comparisons between WT and TADV samples suggest that 1C19 scFv expression is transgene-dependent and does not appear to significantly affect global expression levels of endogenous RNAs. Pearson correlation coefficients (r) between gene expression levels in WT versus transgenic samples are reported in bold in their respective graphs.



Supplementary Figure 2. Western blot analyses to probe for the presence of the 1C19 scFv antibody protein in WT and transgenic midgut samples. Western blots were carried out utilizing a custom antibody specific for the 1C19 scFv protein, as well as an antibody to recognize the 3xHA tag, on dissected midgut tissues from non-blood-fed or 16-hour post-blood-meal WT or TADV-A, TADV-B, or TADV-C mosquitoes. An anti-GAPDH antibody was used as a control. The presence of a 26.3-kDa band confirms the expression of the 1C19 scFv protein in transgenic, but not in WT, mosquito midgut samples. The presence of a 30 kDa band indicates the presence of the 3xHA tag in TADV-B and TADV-C but not in WT or TADV-A mosquitoes.



Supplementary Figure 3. Effect of the anti-DENV scFv on DENV GE in three independent transgenic mosquito lines. DENV GE in WT and transgenic mosquito lines (TADV-A, TADV-B, or TADV-C) following a blood meal infected with DENV-2 (ET300 strain) are shown. DENV GE from mosquito midguts (at 4 dpi) of WT or transgenic mosquitoes were determined using real-time qPCR and calculated using previously published methods. Circles represent WT mosquitoes; black diamonds represent anti-DENV homozygous transgenic mosquitoes; red colored diamonds represent anti-DENV heterozygous transgenic mosquitoes. Horizontal bars represent the mean viral titer. The Mantel-Cox test was used for statistical analysis. ** $p < 0.001$.



Supplementary Figure 4. Survivorship curves for uninfected WT and TADV-A mosquitoes and for DENV-infected WT, wMel, and TADV-A mosquitoes. The x-axis indicates the number of days elapsed after the start of the experiment, and the y-axis indicates the percent of mosquitoes surviving on each elapsed day. **(A)** For the uninfected panel, where the survivorship curves for WT and TADV-A male and female mosquitoes are shown separately, each line represents the accumulated results of 120–180 adult mosquitoes combined from 3 biological replicates. Significant differences in survivorship were observed between WT and TADV-A females, with WT females surviving, on average, 4.5 days longer ($p \leq 0.01$). **(B)** For the infected panels, WT, wMel, and TADV-A females were given a blood meal infected with DENV-1, DENV-2, DENV-3, or DENV-4 (as indicated on respective plot titles). The survivorship of infected mosquitoes was determined over the course of 14 days (the time it takes for the virus to disseminate past the midgut and eventually become transmissible). No significant differences in survivorship were found between WT and TADV-A mosquitoes when infected with DENV-3 and DENV-4, but significant

differences were observed upon infection with DENV-1, with more WT mosquitoes (80%) surviving at 14 dpi than TADV-A mosquitoes (~40%; $p \leq 0.01$). When infected with DENV-2, more *wMel* mosquitoes (>90%) survived at 14 dpi compared to WT and TADV-A mosquitoes

(both ~70%; $p < 0.0001$). The Mantel-Cox test was used to determine statistical significance.
 $*p \leq 0.01$, $***p < 0.0001$.

Supplementary Table 1. Effect of the anti-DENV scFv on DENV-2 GE in three independent mosquito lines. DENV-2 GE are shown below for WT, TADV-A, TADV-B, and TADV-C mosquito lines following a blood meal infected with the DENV-2 ET300 strain. Midgut samples were collected 4 dpi, and GE were determined using real-time RT-qPCR and calculated using previously published methods.

Mosquito strain	GE of virus RNA/mosquito midgut at 4 dpi	Virus-positive mosquitoes/ Total mosquitoes (% infection rate)
WT	4.5×10^4	24/26 (92.3%)
TADV-A	6.1×10^1	17/37 (45.9%)
TADV-B	1.5×10^2	25/40 (62.5%)
TADV-C	2.0×10^2	25/35 (71.4%)

Supplementary Table 2: Primers utilized to generate anti-DENV scFv used in this study.

Primer	Primer Sequence, 5' to 3'	Source
tdTomato marker 984.1A 984.1B	GACGGTACGATCCACCGGTCGCCACCATGGTGAGCAAGGGCGAGG AGGTCATCAAAGAGT TGGTATGGCTGATTATGATCTAGAGTCGCGGCCGCCTACTTGTACAG CTCGTCCATGCCG	Gene-synthesized vector
Carboxypeptidase promoter 984.2A 984.2B	ATGGTTAATTCGAGCTCGCCCGGGTCTAGGGAATTCGTCAATAA AAAAATACGTTCAA CTCCTCGCCCTTGCTCACCATGTTTAAACTTTCCCAACTAACCGATA CACACTAACCTG	Genomic <i>Ae. aegypti</i> DNA
GFP marker 984.3A 984.3B	AGTGTGTATCGGTTAGTTGGGAAAGTTTAAACATGGTGAGCAAGGG CGAGGAGCTGTTTAC TGATTTGTTATTTTAAAAACGATTCATTCTAGTTAATTAATTACTTGT ACAGCTCGTCCATGCC	pMos[3xP3-eGFP]
p10 3' UTR 984.4A 984.4B	GGACGAGCTGTACAAGTAATTAATTAAGTGAATGAATCGTTTTTA AAATAACAAAT TCCCCGGGCGAGCTCGAATTGGCGCGCCCGCCGTTAACTCGAATC GCTATCCAAGC	pJFRC81-10XUAS-IVS-Syn21-GFP-p10
G(4)-S linker 984B.C1 984B.C2	TTCGGTCAGGGAACCAAAGTGGATATTAAGGGCGGTTCCGGTGGCA GCGGCGGCTCCGGTGGCAGCTACCCCTACGACGTGCCCG TGTTATTTTAAAAACGATTCATTCTAGTTAATTAATCAGGCGTAATC TGGCACGTCGTAC	<i>ninaE</i> [SBP-His] vector

Supplementary Table 3. Diagnostic primers used for inverse PCR (iPCR) assays, zygosity confirmation, pan-DENV serotype detection, and wMel infection confirmation.

<i>piggyBac</i> Primers			
Reaction	Primer Name		Primer Sequence, 5' to 3'
5' (1st Round PCR)	991.5F1		GACGCATGATTATCTTTTACGTGAC
	991.5R1		TGACACTTACCGCATTGACA
5' (2nd Round PCR)	991.5F2		GCGATGACGAGCTTGTGGTG
	991.5R2		TCCAAGCGGCGACTGAGATG
3' (1st Round PCR)	991.3F1		CAACATGACTGTTTTTAAAGTACAAA
	991.3R1		GTCAGAAACAACCTTGGCACATATC
3' (2nd Round PCR)	991.3F2		CCTCGATATACAGACCGATAAAAC
	991.3R2		TGCATTTGCCTTTCGCCTTAT
<i>Zygosity Primers</i>			
Reaction	Line	Primer Name	Primer Sequence, 5' to 3'
Forward primer	TADV-A	1018.S19	CCAAGTCGTCAACTTGTGACTG
	TADV-B	1018.S73	TAAAAACATAAACAACGACC

	TADV-C	1018.S80	GCTCTCACCGTTGAAAATTTAT
Reverse primer	TADV-A	1018.S21	GGACCCAATTGTTACTACACCTATTTTC
	TADV-B	1018.S74	AAAATAAATCATTCTGAGTTTGT
	TADV-C	1018.S82	CAGGGTCCTAAAATGTTCAATG
DENV RT-qPCR Primers			
Primer name		Primer Sequence, 5' to 3'	
DENV-F		ACGTGCACACATGGACAGA	
DENV-R		ACTGAGCGGATTCCACAAA	
wMel Primers			
Primer name		Primer Sequence, 5' to 3'	
wMel-F		CAAATTGCTCTTGTCTGTGG	
wMel-R		GGGTGTTAAGCAGAGTTACGG	

Supplementary Table 4 .Quantification of total RNA expression in WT, TADV-A, TADV-B, and TADV-C mosquito midguts prior to blood meal (NBF) and 24-hours post-blood feeding (PBM). Both raw read counts and normalized TPM values are included.

https://docs.google.com/spreadsheets/d/1Xvuw5xwCwE8_pU_-coBptAY1hK9DX0GRzAUijRooZvk/edit?usp=sharing

References

1. Murrell, S., Wu, S.-C. & Butler, M. Review of dengue virus and the development of a vaccine. *Biotechnol. Adv.* **29**, 239–247 (2011).
2. Mustafa, M. S., Rasotgi, V., Jain, S. & Gupta, V. Discovery of fifth serotype of dengue virus (DENV-5): A new public health dilemma in dengue control. *Armed Forces Med. J. India* **71**, 67–70 (2015).
3. Whitehorn, J. Dengue Fever Viruses. in *eLS* (John Wiley & Sons, Ltd, 2001).
4. Rajapakse, S. Dengue shock. *J. Emerg. Trauma Shock* **4**, 120–127 (2011).
5. Messina, J. P. *et al.* Global spread of dengue virus types: mapping the 70 year history. *Trends Microbiol.* **22**, 138–146 (2014).
6. Bhatt, S. *et al.* The global distribution and burden of dengue. *Nature* **496**, 504–507 (2013).
7. Brady, O. J. *et al.* Refining the global spatial limits of dengue virus transmission by evidence-based consensus. *PLoS Negl. Trop. Dis.* **6**, e1760 (2012).
8. Shepard, D. S., Undurraga, E. A., Halasa, Y. A. & Stanaway, J. D. The global economic burden of dengue: a systematic analysis. *Lancet Infect. Dis.* **16**, 935–941 (2016).
9. Selck, F. W., Adalja, A. A. & Boddie, C. R. An estimate of the global health care and lost productivity costs of dengue. *Vector Borne Zoonotic Dis.* **14**, 824–826 (2014).
10. World Health Organization. *Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control.* (World Health Organization, 2009).
11. Hadinegoro, S. R. *et al.* Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease. *N. Engl. J. Med.* **373**, 1195–1206 (2015).
12. Capeding, M. R. *et al.* Clinical efficacy and safety of a novel tetravalent dengue vaccine in

- healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. *Lancet* **384**, 1358–1365 (2014).
13. Dengue vaccine: WHO position paper – July 2016. *Wkly. Epidemiol. Rec.* **91**, 349–364 (2016).
 14. Dans, A. L., Dans, L. F., Lansang, M. A. D., Silvestre, M. A. A. & Guyatt, G. H. Controversy and debate on dengue vaccine series-paper 1: review of a licensed dengue vaccine: inappropriate subgroup analyses and selective reporting may cause harm in mass vaccination programs. *J. Clin. Epidemiol.* **95**, 137–139 (2018).
 15. Hadinegoro, S. R. S. *et al.* Controversy and debate on dengue vaccine series-paper 2: response to review of a licensed dengue vaccine: inappropriate subgroup analyses and selective reporting may cause harm in mass vaccination programs. *J. Clin. Epidemiol.* **95**, 140–141 (2018).
 16. Gibbons, R. V. & Vaughn, D. W. Dengue: an escalating problem. *BMJ* **324**, 1563–1566 (2002).
 17. Scott, T. W. & Takken, W. Feeding strategies of anthropophilic mosquitoes result in increased risk of pathogen transmission. *Trends Parasitol.* **28**, 114–121 (2012).
 18. Gloria-Soria, A., Brown, J. E., Kramer, V., Hardstone Yoshimizu, M. & Powell, J. R. Origin of the dengue fever mosquito, *Aedes aegypti*, in California. *PLoS Negl. Trop. Dis.* **8**, e3029 (2014).
 19. Kraemer, M. U. G. *et al.* The global distribution of the arbovirus vectors *Aedes aegypti* and *Ae. albopictus*. *Elife* **4**, e08347 (2015).
 20. Carvalho, M. S., Honorio, N. A., Garcia, L. M. T. & Carvalho, L. C. de S. *Aedes aegypti* control in urban areas: A systemic approach to a complex dynamic. *PLoS Negl. Trop. Dis.*

- 11**, e0005632 (2017).
21. Haug, C. J., Kieny, M. P. & Murgue, B. The Zika Challenge. *N. Engl. J. Med.* **374**, 1801–1803 (2016).
 22. Gatton, M. L. *et al.* The importance of mosquito behavioural adaptations to malaria control in Africa. *Evolution* **67**, 1218–1230 (2013).
 23. Moyes, C. L. *et al.* Contemporary status of insecticide resistance in the major Aedes vectors of arboviruses infecting humans. *PLoS Negl. Trop. Dis.* **11**, e0005625 (2017).
 24. Yakob, L., Funk, S., Camacho, A., Brady, O. & Edmunds, W. J. Aedes aegypti Control Through Modernized, Integrated Vector Management. *PLoS Curr.* **9**, (2017).
 25. Champer, J., Buchman, A. & Akbari, O. S. Cheating evolution: engineering gene drives to manipulate the fate of wild populations. *Nat. Rev. Genet.* **17**, 146–159 (2016).
 26. Lacroix, R. *et al.* Open field release of genetically engineered sterile male Aedes aegypti in Malaysia. *PLoS One* **7**, e42771 (2012).
 27. Carvalho, D. O. *et al.* Suppression of a Field Population of Aedes aegypti in Brazil by Sustained Release of Transgenic Male Mosquitoes. *PLoS Negl. Trop. Dis.* **9**, e0003864 (2015).
 28. Aliota, M. T., Peinado, S. A., Velez, I. D. & Osorio, J. E. The wMel strain of Wolbachia Reduces Transmission of Zika virus by Aedes aegypti. *Sci. Rep.* **6**, 28792 (2016).
 29. Walker, T. *et al.* The wMel Wolbachia strain blocks dengue and invades caged Aedes aegypti populations. *Nature* **476**, 450–453 (2011).
 30. Moreira, L. A. *et al.* A Wolbachia symbiont in Aedes aegypti limits infection with dengue, Chikungunya, and Plasmodium. *Cell* **139**, 1268–1278 (2009).
 31. Schmidt, T. L. *et al.* Local introduction and heterogeneous spatial spread of dengue-

- suppressing Wolbachia through an urban population of *Aedes aegypti*. *PLoS Biol.* **15**, e2001894 (2017).
32. Sinkins, S. P. & Gould, F. Gene drive systems for insect disease vectors. *Nat. Rev. Genet.* **7**, 427–435 (2006).
 33. Macias, V. M., Ohm, J. R. & Rasgon, J. L. Gene Drive for Mosquito Control: Where Did It Come from and Where Are We Headed? *Int. J. Environ. Res. Public Health* **14**, (2017).
 34. Franz, A. W. E. *et al.* Engineering RNA interference-based resistance to dengue virus type 2 in genetically modified *Aedes aegypti*. *Proc. Natl. Acad. Sci. U. S. A.* **103**, 4198–4203 (2006).
 35. Mathur, G. *et al.* Transgene-mediated suppression of dengue viruses in the salivary glands of the yellow fever mosquito, *Aedes aegypti*. *Insect Mol. Biol.* **19**, 753–763 (2010).
 36. Yen, P.-S., James, A., Li, J.-C., Chen, C.-H. & Failloux, A.-B. Synthetic miRNAs induce dual arboviral-resistance phenotypes in the vector mosquito *Aedes aegypti*. *Communications Biology* **1**, (2018).
 37. Jupatanakul, N. *et al.* Engineered *Aedes aegypti* JAK/STAT Pathway-Mediated Immunity to Dengue Virus. *PLoS Negl. Trop. Dis.* **11**, e0005187 (2017).
 38. Burton, D. R., Poignard, P., Stanfield, R. L. & Wilson, I. A. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. *Science* **337**, 183–186 (2012).
 39. Isaacs, A. T. *et al.* Transgenic *Anopheles stephensi* coexpressing single-chain antibodies resist *Plasmodium falciparum* development. *Proc. Natl. Acad. Sci. U. S. A.* **109**, E1922–30 (2012).
 40. Sumitani, M. *et al.* Reduction of malaria transmission by transgenic mosquitoes expressing

- an antiparasite antibody in their salivary glands. *Insect Mol. Biol.* **22**, 41–51 (2013).
41. Isaacs, A. T. *et al.* Engineered resistance to Plasmodium falciparum development in transgenic Anopheles stephensi. *PLoS Pathog.* **7**, e1002017 (2011).
 42. Smith, S. A. *et al.* The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein. *MBio* **4**, e00873–13 (2013).
 43. Hudson, P. J. & Kortt, A. A. High avidity scFv multimers; diabodies and triabodies. *J. Immunol. Methods* **231**, 177–189 (1999).
 44. Moreira, L. A. *et al.* Robust gut-specific gene expression in transgenic Aedes aegypti mosquitoes. *Proc. Natl. Acad. Sci. U. S. A.* **97**, 10895–10898 (2000).
 45. Berghammer, A. J., Klingler, M. & Wimmer, E. A. Genetic techniques: A universal marker for transgenic insects. *Nature* **402**, 370–371 (1999).
 46. Matthews, B. J. Improved Aedes aegypti mosquito reference genome assembly enables biological discovery and vector control. *bioRxiv* Available at: doi: <https://doi.org/10.1101/240747>. (Accessed: 9th June 2018)
 47. O’Neill, S. L. The Use of Wolbachia by the World Mosquito Program to Interrupt Transmission of Aedes aegypti Transmitted Viruses. in *Dengue and Zika: Control and Antiviral Treatment Strategies* (eds. Hilgenfeld, R. & Vasudevan, S. G.) 355–360 (Springer Singapore, 2018).
 48. Imler, J.-L. & Martins, N. Faculty of 1000 evaluation for Field- and clinically derived estimates of Wolbachia-mediated blocking of dengue virus transmission potential in Aedes aegypti mosquitoes. *F1000 - Post-publication peer review of the biomedical literature* (2018). doi:10.3410/f.732369982.793541519

49. Ye, Y. H. *et al.* Wolbachia Reduces the Transmission Potential of Dengue-Infected *Aedes aegypti*. *PLoS Negl. Trop. Dis.* **9**, e0003894 (2015).
50. Ferguson, N. M. *et al.* Modeling the impact on virus transmission of Wolbachia-mediated blocking of dengue virus infection of *Aedes aegypti*. *Sci. Transl. Med.* **7**, 279ra37 (2015).
51. doi:10.1101/344697
52. Gantz, V. M. *et al.* Highly efficient Cas9-mediated gene drive for population modification of the malaria vector mosquito *Anopheles stephensi*. *Proc. Natl. Acad. Sci. U. S. A.* **112**, E6736–43 (2015).
53. Zou, G. *et al.* Resistance analysis of an antibody that selectively inhibits dengue virus serotype-1. *Antiviral Res.* **95**, 216–223 (2012).
54. Lai, C.-J. *et al.* Epitope determinants of a chimpanzee dengue virus type 4 (DENV-4)-neutralizing antibody and protection against DENV-4 challenge in mice and rhesus monkeys by passively transferred humanized antibody. *J. Virol.* **81**, 12766–12774 (2007).
55. Yamanaka, A., Kotaki, T. & Konishi, E. A mouse monoclonal antibody against dengue virus type 1 Mochizuki strain targeting envelope protein domain II and displaying strongly neutralizing but not enhancing activity. *J. Virol.* **87**, 12828–12837 (2013).
56. Budigi, Y. *et al.* Neutralization of antibody-enhanced dengue infection by VIS513, a pan serotype reactive monoclonal antibody targeting domain III of the dengue E protein. *PLoS Negl. Trop. Dis.* **12**, e0006209 (2018).
57. Long, F. *et al.* Structural basis of a potent human monoclonal antibody against Zika virus targeting a quaternary epitope. *Proc. Natl. Acad. Sci. U. S. A.* 201815432 (2019).
58. Sun, H., Chen, Q. & Lai, H. Development of Antibody Therapeutics against Flaviviruses. *Int. J. Mol. Sci.* **19**, (2017).

59. Fernandez, E. *et al.* Mouse and Human Monoclonal Antibodies Protect against Infection by Multiple Genotypes of Japanese Encephalitis Virus. *MBio* **9**, (2018).
60. Smith, S. A. *et al.* Isolation and Characterization of Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity against Chikungunya Virus. *Cell Host Microbe* **18**, 382 (2015).
61. Goo, L. *et al.* A protective human monoclonal antibody targeting the West Nile virus E protein preferentially recognizes mature virions. *Nat Microbiol* **4**, 71–77 (2019).
62. Yusakul, G., Sakamoto, S., Pongkitwitoon, B., Tanaka, H. & Morimoto, S. Effect of linker length between variable domains of single chain variable fragment antibody against daidzin on its reactivity. *Biosci. Biotechnol. Biochem.* **80**, 1306–1312 (2016).
63. Corby-Harris, V. *et al.* Activation of Akt signaling reduces the prevalence and intensity of malaria parasite infection and lifespan in *Anopheles stephensi* mosquitoes. *PLoS Pathog.* **6**, e1001003 (2010).
64. Gibson, D. G. *et al.* Enzymatic assembly of DNA molecules up to several hundred kilobases. *Nat. Methods* **6**, 343–345 (2009).
65. Kokoza, V., Ahmed, A., Wimmer, E. A. & Raikhel, A. S. Efficient transformation of the yellow fever mosquito *Aedes aegypti* using the piggyBac transposable element vector pBac[3xP3-EGFP afm]. *Insect Biochem. Mol. Biol.* **31**, 1137–1143 (2001).
66. Chen, Z., Chen, H.-C. & Montell, C. TRP and Rhodopsin Transport Depends on Dual XPORT ER Chaperones Encoded by an Operon. *Cell Rep.* **13**, 573–584 (2015).
67. Li, M., Bui, M., Yang, T., White, B. & Akbari, O. Germline Cas9 Expression Yields Highly Efficient Genome Engineering in a Major Worldwide Disease Vector, *Aedes aegypti*. (2017). doi:10.1101/156778

68. Akbari, O. S. *et al.* The developmental transcriptome of the mosquito *Aedes aegypti*, an invasive species and major arbovirus vector. *G3* **3**, 1493–1509 (2013).
69. Huang, A. M., Rehm, E. J. & Rubin, G. M. Recovery of DNA sequences flanking P-element insertions in *Drosophila*: inverse PCR and plasmid rescue. *Cold Spring Harb. Protoc.* **2009**, db.prot5199 (2009).
70. Matthews, B. J. *et al.* Improved *Aedes aegypti* mosquito reference genome assembly enables biological discovery and vector control. *bioRxiv* 240747 (2017).
doi:10.1101/240747
71. Dobin, A. *et al.* STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* **29**, 15–21 (2013).
72. Bhadauria, V. *Next-generation Sequencing and Bioinformatics for Plant Science*. (Caister Academic Press, 2017).
73. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* **15**, 550 (2014).
74. Simpson, R. J. SDS-PAGE of Proteins. *CSH Protoc.* **2006**, (2006).
75. Duchemin, J.-B. *et al.* Zika vector transmission risk in temperate Australia: a vector competence study. *Viol. J.* **14**, 108 (2017).
76. Joubert, D. A. *et al.* Establishment of a *Wolbachia* Superinfection in *Aedes aegypti* Mosquitoes as a Potential Approach for Future Resistance Management. *PLoS Pathog.* **12**, e1005434 (2016).